Summary

Advice

The technology described in this briefing is InterDry. It is used for treating intertrigo, a common inflammatory skin rash that usually develops in skin folds, such as in the groin, under the breast or in the armpits.
The innovative aspects are that the technology is designed to target all 3 factors associated with intertrigo: moisture, bacteria or fungi and friction from skin-to-skin contact.
The intended place in therapy would be as an alternative to other treatment options used in managing intertrigo. This may include topical or systemic antimicrobial agents and corticosteroids, and absorptive materials such as gauze.
The main points from the evidence summarised in this briefing are from 1 prospective single-arm observational study, 2 case series and 2 case reports including a total of 28 adults with intertrigo or complications associated with skin folds. Evidence suggests that InterDry may help to reduce the symptoms of intertrigo, including itching or burning, loss of skin layers, secondary lesions, redness and odour.
Key uncertainties around the technology are that the available evidence is very limited in quantity and quality. Well-designed comparative studies would be helpful to determine the benefits over current management options. The care pathway for intertrigo in the UK is not well defined and standard care may vary.
The cost of InterDry is £43.07 for the 25 cm × 91 cm pouch and £105.95 for the 25 cm × 366 cm roll (exclusive of VAT). The resource impact would be an initial cost increase compared with existing treatment options. This may be offset if the use of InterDry reduces overall treatment time and associated costs. There is no published evidence to support these claims.